Eli Lilly and Company (LLY) Comes Out Against the Use of GLP-1 Drugs for “Cosmetic Weight Loss” as Obesity in the US Remains Near Record Highs

wccftech.com:

This is not investment advice. The author has no position in any of the stocks mentioned. Wccftech.com has a disclosure and ethics policy.

Eli Lilly and Company (LLY) is out today with a much-needed qualifier regarding the emergent probability of its breakthrough GLP-1 weight loss treatments ending up as "lifestyle drugs of choice."

To wit, Eli Lilly and Company has now published an open letter, noting among other things:

"Mounjaro and Zepbound are indicated for the treatment of serious diseases; they are not approved for – and should not be used for – cosmetic weight loss."

While addressing the emerging issues with off-label Tirzepatide-based cocktails, Eli Lilly and Company writes:

"Lilly is extremely concerned that some of the compounded Tirzepatide that Lilly has tested has contained high amounts of impurities, and, in at least one instance, was actually nothing more than sugar alcohol."

Finally, the pharma giant announced that it has commenced legal action against spas and other establishments that are selling products "claiming to contain the active pharmaceutical ingredient (API) for Tirzepatide."

For the benefit of those who might not be aware, Glucagon-Like Peptide-1 (GLP-1) hormone plays a critical role in regulating hunger by stimulating the release of insulin in the pancreas, blocking the unhelpful release of glucagon after meals to prevent excess glucose from entering the bloodstream, and slowing the emptying of the stomach to reduce the overall food intake. Simultaneously, GLP-1 receptors also help suppress the brain's stress response and reward/reinforcement mechanism to increase the feeling of satiation.

Eli Lilly and Company sells its Tirzepatide GLP-1 cocktail under the Mounjaro and Zepbound labels, with the